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Primary haemostasis: Sticky fingers cement the relationship
Kenneth J. Clemetson
Platelet aggregation to form a haemostatic plug, or
thrombus, plays a key role in preventing bleeding from
a wound. Recent studies have provided new insights
into how platelet receptors are deployed during the
interactions with the vascular subendothelial matrix
that lead to haemostatic plug formation.
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Platelets are critical for the maintenance of the integrity of
the vascular system and the prevention of bleeding from
wounds. These small, anuclear cellular bodies are formed
from their precursor cell, the megakaryocyte, and circulate
for eight to ten days in the blood. When they encounter
subendothelial matrix exposed by injury to a vessel,
platelets adhere, are activated and become adhesive for
other platelets so that they aggregate (Figure 1). The
resulting aggregate, or thrombus, is stabilised in a continu-
ing process by fibrin formation. The development of the
initial haemostatic plug by platelets is referred to as
primary haemostasis. A subsequent process of ‘platelet
retraction’, involving myosin and actin filaments within
platelets that are linked via the integrin αIIbβ3 to extra-
cellular fibrin, draws the edges of a wound together,
reducing bleeding and supporting the healing process.
Platelet remnants are removed later by phagocytes as
endothelial cells spread back to cover the injury site. 
Thrombosis is the pathological version of haemostasis, and
a factor in its development may be a disequilibrium
between the positive and negative feedback mechanisms
that control the growth of a thrombus and limit its size to
that adequate to deal with a bleeding injury. In thrombo-
sis, unrestrained growth of a thrombus may lead to myocar-
dial infarction by blockage of a critical cardiac vessel, or
stroke as a result of a blockage of more remote vessels by
pieces — known as emboli — broken off an unstable
thrombus. The inhibition of platelet receptors or feedback
loops has been shown to reduce the incidence of major car-
diovascular disease, and there is great interest in develop-
ing improved strategies for its prevention. For this, a better
understanding of the basic mechanisms involved in
primary haemostasis is seen as absolutely essential.
Over the past 25 years, the structures and roles of the major
platelet receptors involved in adhesion and aggregation
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Platelet adhesion, activation and aggregation on exposed
subendothelium, for example at a wound site. This process evolves
from a rolling contact between the platelet and the subendothelial
surface — mediated by interaction between GPIb and von Willebrand
factor (vWf) — to platelet activation involving granule release, firm
binding via activated integrins α2β1 and αIIbβ3, and spreading. Such
activated platelets become adhesive for other platelets, and a
thrombus made up of aggregated platelets — interacting via fibrinogen
bound to their surface αIIbβ3 receptors — is formed. The
subendothelium is covered, or a sectioned vessel is sealed off,
preventing blood loss to surrounding tissue. Platelet receptors and
their subendothelial binding sites are indicated.
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have been unravelled. Genetic disorders where these
receptors are absent or defective have certainly facilitated
elucidation of their roles. Thus, GPIb is the platelet recep-
tor for von Willebrand factor, which is involved in platelet
adhesion at several stages; integrin αIIbβ3 is a receptor for
several adhesive proteins that contain the sequence
arginine–glycine–aspartate (RGD), but mainly fibrinogen;
and several platelet glycoproteins, in particular the integrin
α2β1 and GPVI, are collagen receptors. In addition, a large
number of receptors involved in positive or negative feed-
back control of platelet aggregation have been identified,
including those for ADP, prostaglandins, thromboxanes,
serotonin, platelet activating factor (PAF) and thrombin.
Attempts to elucidate in vivo haemostatic processes have
been facilitated by the ability to simulate relevant in vivo
conditions in vitro. This has involved the development of
subendothelial-like matrices exposed to blood flow in
perfusion chambers under conditions of shear similar to
those encountered in various vessels [1,2]. It is well estab-
lished that shear varies enormously, depending on vessel
cross-section, being lowest in the aorta and highest in the
capillaries and arterioles. von Willebrand factor is critical
for haemostasis at high shear rates and is dispensable at
low shear rates; collagen receptors are important at all
shear rates. The main components of the subendothelium
involved in platelet adhesion and activation are the
various types of collagen, as well as von Willebrand factor
bound via its A3 domain to specific sites on collagens.
How these various receptors interact with the matrix to
produce regulated platelet adhesion and activation is the
subject of much on-going research. 
This is well illustrated by the work of Savage et al. [3], who
have recently used these techniques together with confo-
cal videomicroscopy to examine how platelets bind and are
displaced on a collagen-coated surface subjected to various
shear rates. The number of platelets that adhere to the
surface and the size of the thrombi that they form, as well
as the movement of individual platelets, can be quantified
using this approach. Various antibodies were used to
inhibit specific receptors and thereby test their role in the
various stages of adhesion, activation and aggregation. As
in earlier studies, inhibition of integrin αIIbβ3 allowed
single platelet adhesion, but prevented thrombus growth
at all shear rates by blocking platelet–platelet aggregation
via fibrinogen. Inhibition of von Willebrand factor binding
to collagen, or of von Willebrand factor binding to its
platelet receptor GPIb, prevented platelet adhesion com-
pletely at a shear rate of 1500 sec–1, partly at 500 sec–1 and
not at all at 100 sec–1. Inhibition of the integrin α2β1 partly
blocked adhesion as well as reducing aggregate size. 
The major advantage of real-time confocal videomicroscopy
is that the movements of single platelets can be followed
and the average velocity of platelets interacting with a
surface thereby determined. It has long been thought that
the main function of the interaction between GPIb and
von Willebrand factor is to initiate binding of platelets
under high shear conditions, but it was earlier assumed
that this is more or less an all-or-nothing effect, with a
platelet either being stopped by the interaction or having
a grazing encounter. But actually platelets are slowed by a
series of multiple weak interactions, involving making and
breaking single attachments between different GPIb
receptors and von Willebrand factor molecules on the
surface so that, at any given time, there are always some
interactions holding the platelet in contact with the
surface but it can nevertheless move across the surface.
What brings this process to an end? One possibility is that,
if the platelet is near the edge of a vascular lesion, it can
move off the subendothelium onto endothelial cells,
become detached and return to the circulation. 
Recent studies with transfected cells making the GPIb
complex have shown that these too roll on a von-
Willebrand-factor-coated surface, though no firm adhesion
was detected [4]. In the perfusion chamber system used,
platelets move a certain distance and then adhere firmly.
This definitive adhesion was prevented if integrins α2β1
and αIIbβ3 were both inhibited, and most of the platelets
were then displaced further. Firm adhesion was also pre-
vented by inhibition of integrin α2β1 in the presence of
prostaglandin E1 to block activation of αIIbβ3. The
binding via αIIbβ3 might be to the RGD sequence on von
Willebrand factor bound to collagen [2,5], or it might be to
other RGD-containing adhesive proteins, such as fibrino-
gen, vitronectin or fibronectin which are released from
activated platelets. Similar results were obtained when
subendothelial matrix was used instead of collagen type I. 
Does integrin α2β1 need to be activated for it to bind to col-
lagen? Integrin αIIbβ3 does need to be activated to bind to
the RGD sequence in fibrinogen and other proteins. The
situation with regard to α2β1 and collagen is much less clear.
It was assumed that α2β1 is constitutively active, simply
because platelets aggregate in response to collagen and α2β1
was the first, and for a long time the only, characterised
platelet collagen receptor. But the characterisation of other
collagen receptors, in particular GPVI, has cast doubt on this
earlier assumption and recent studies comparing platelet
binding to insoluble and ‘soluble’ collagen have provided
the first real evidence that integrin activation does have an
important role in platelet adhesion and stimulation [6].
Integrins αIIbβ3 and α2β1 are probably both activated as a
result of platelet binding to the subendothelium via the
interaction between von Willebrand factor and GPIb. As
this latter interaction requires high shear stress, how does
one explain platelet binding to the subendothelium and
activation under low shear conditions? Binding to collagen
is probably involved — platelets are aggregated by
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collagen, and this is inhibited by antibodies to a number of
platelet collagen receptors as well as to α2β1. So there are
probably mechanisms for activating α2β1 during platelet
interactions with collagen. GPVI is a prime candidate for
being such a collagen receptor, and is also important for
activation of αIIbβ3 under such conditions [7]. GPVI-
specific agonists, such as collagen-related peptides, are
capable of activating αIIbβ3. 
Platelets lacking GPVI can nevertheless still be acti-
vated, albeit weakly, by collagen; they do not aggregate
but do show increased fibrinogen binding, indicating that
there is some residual activation of αIIbβ3 [8]. This indi-
cates that, while GPVI has an important role in activation
of both integrins, other collagen receptors, including
probably α2β1 [9], permit some αIIbβ3 activation in its
absence. In order to test the activation state of α2β1 con-
vincingly, it will be necessary to develop specific,
defined reagents for use as probes, in the same way that
fibrinogen or specific monoclonal antibodies are used to
probe for αIIbβ3 activation. The ‘soluble’ collagen
described above may be adequate for this role, but will
need to be characterised better. 
The recent studies have revealed platelet adhesion and
activation to be a stepwise process (Figure 2) with strong
parallels to leukocyte migration at sites of inflammation.
In both cases, weak ‘rolling’ interactions — mediated by
GPIb and von Willebrand factor in the case of platelet
adhesion, and selectins and their complex carbohydrate
ligands in the case of leukocytes — are followed by firm
adhesion mediated by integrins.
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Steps in platelet activation during interaction with subendothelial
components. (a) Initial rolling contact between platelet GPIb and the A1
domain of von Willebrand factor, bound to collagen by its A3 domain,
slows down and activates platelets allowing firm adhesion to occur.
(b) The platelet has been stalled, activated and stronger binding now
occurs via integrins to collagen and other adhesive proteins.
Simultaneously, the adhesion process is enhanced via release of granule
contents and cytoskeletal activation. (c) The activated platelet continues
to spread on the subendothelium and more receptors are engaged.
Other platelets can bind to the surface-bound platelet via activated αIIbβ3
receptors and plasma or released platelet fibrinogen, and these become
activated in their turn by granule contents and clustering of receptors.
